The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules

Journal of Neuroscience Research

Volumn 86, Issue 8, 2008, Pages 1711-1720

  Gandhi, Payai N ^a   Wang, Xinglong ^b   Zhu, Xiongwei ^b   Chen, Shu G ^b   Wilson Delfosse, Amy L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Leucine rich repeat kinase 2; Neurodegeneration; Parkinson's disease; R1441C; Tubulin

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; GUANINE NUCLEOTIDE; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MASS SPECTROMETRY; MICROTUBULE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; GTP PHOSPHOHYDROLASES; HUMANS; MICE; MICROTUBULES; MOLECULAR SEQUENCE DATA; MUTATION; NIH 3T3 CELLS; PARKINSON DISEASE; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES;

EID: 45549085874     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21622     Document Type: Article

References (44)

1. Abysalh JC, Kuchnicki LL, Larochelle DA. 2003. The identification of patsl, a novel gene locus required for cytokinesis in Dictyostelium discoideum. Mol Biol Cell 14:14-25.
2. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K. 2002. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 277:2112-2117.
3. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I. 2004. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 3:515-533.
4. Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T. 2005. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128:3000-3011.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
6. Bialik S, Bresnick AR, Kimchi A. 2004. DAP-kinase-mediated morphological changes are localization dependent and involve myosin-II phosphorylation. Cell Death Differ 11:631-644.
7. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL. 2006. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60:557-569.
8. Bosgraaf L, Van Haastert PJ. 2003. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5-10.
9. Bosgraaf L, Russcher H, Smith JL, Wessels D, Soll DR, Van Haastert PJ. 2002. A novel cGMP signalling pathway mediating myosin phosphorylation and Chemotaxis in Dictyostelium. EMBO J 21:4560-4570.
10. Brinkley BR, Barham SS, Barranco SC, Fuller GM. 1974. Rotenone inhibition of spindle microtubule assembly in mammalian cells. Exp Cell Res 85:41-46.
11. Burke D, Gasdaska P, Hartwell L. 1989. Dominant effects of tubulin overexpression in Saccharomyces cerevisiae. Mol Cell Biol 9:1049-1059.
12. Cappelletti G, Surrey T, Maci R. 2005. The parkinsonism producing neurotoxin MPP affects microtubule dynamics by acting as a destabilising factor. FEBS Lett 579:4781-4786.
13. 2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 16:998-1008.
14. Crosby AH. 2003. Disruption of cellular transport: a common cause of neurodegeneration? Lancet Neurol 2:311-316.
15. Dachsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, Bailey RM, Hines JH, Szutu J, Madden B, Petrucelli L, Farrer MJ. 2007. Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord [E-pub ahead of print].
16. Ding J, Liu JJ, Kowal AS, Nardine T, Bhattacharya P, Lee A, Yang Y. 2002. Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin. J Cell Biol 158:427-433.
17. Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM. 2005. LRRK2 mutations in Parkinson disease. Neurology 65:738-740.
18. Galloway PG, Mulvihill P, Perry G. 1992. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 140:809-822.
19. Garcia ML, Cleveland DW. 2001. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol 13:41-48.
20. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223-232.
21. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V. 2005. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42:e65.
22. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB. 2004. Gene expression profiung of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111:1543-1573.
23. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. 2007. The Parkinson's disease associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (in press).
24. Hernandez D, Paisan Ruiz C, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, Dickson D, Wavrant Devrieze F, Hardy J, Singleton A. 2005. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389:137-139.
25. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. 1998. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705.
26. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW. 2005. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786-2796.
27. Kim JM, Lee KH, Jeon YJ, Oh JH, Jeong SY, Song IS, Kim JM, Lee DS, Kim NS. 2006. Identification of genes related to Parkinson's disease using expressed sequence tags. DNA Res 13:275-286.
28. Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
29. Lee HJ, Khoshaghideh F, Lee S, Lee SJ. 2006. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur J Neurosci 24:3153-3162.
30. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ. 1988. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol 155:9-15.
31. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. 2006. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52:587-593.
32. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ. 2005. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6:171-177.
33. Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28:57-87.
34. Noureddine MA, Li YJ, van der Walt JM, Walters R, Jewett RM, Xu H, Wang T, Walter JW, Scott BL, Hulette C, Schmechel D, Stenger JE, Dietrich F, Vance JM, Hauser MA. 2005. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov Disord 20:1299-1309.
35. Przedborski S, Jackson-Lewis V. 1998. Mechanisms of MPTP toxicity. Mov Disord 13:35-38.
36. Puis I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH. 2003. Mutant dynactin in motor neuron disease. Nat Genet 33:455-456.
37. Ren Y, Zhao J, Feng J. 2003. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 23:3316-3324.
38. Smith DB, Johnson KS. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31-40.
39. Takai Y, Sasaki T, Matozaki T. 2001. Small GTP-binding proteins. Physiol Rev 81:153-208.
40. Tanner CM, Ben-Shlomo Y. 1999. Epidemiology of Parkinson's disease. Adv Neurol 80:153-159.
41. Weinstein B, Solomon F. 1990. Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubukn and beta-tubulin. Mol Cell Biol 10:5295-5304.
42. Yang F, Jiang Q, Zhao J, Ren Y, Sutton MD, Feng J. 2005. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 280:17154-17162.
43. Yoo MS, Chun HS, Son JJ, DeGiorgio LA, Kim DJ, Peng C, Son JH. 2003. Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease. Brain Res Mol Brain Res 110:76-84.
44. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, Yang HW, Terada S, Nakata T, Takei Y, Saito M, Tsuji S, Hayashi Y, Hirokawa N. 2001. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 105:587-597.